A Vaccine to Prevent Herpes Zoster and Postherpetic Neuralgia in Older Adults

1,410 citations recorded by the source corpus.

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

Systematic review of incidence and complications of herpes zoster: towards a global perspective (2014, background): “However, based on the current literature, there is no conclusive evidence as to whether varicella vaccination programmes have been associated with an increase in the incidence of HZ.”
Recommendations for the management of herpes zoster. (2007, background): “A prospective study of 56 patients with such complaints in a general practice setting, together with 81 matched control blood donors, was undertaken ; none of the study subjects developed a rash, and the presence of positive serologic test results (for IgM, IgG, and IgA) and positive PCR results fro”
Scientific and medical aspects of ozone therapy. State of the art. (2006, background): “It must be mentioned that a new vaccine can significantly reduce the incidence of herpes zoster infection and post-herpetic neuralgia (49).”
Guidelines for Preventing Infectious Complications among Hematopoietic Cell Transplant Recipients: A Global Perspective (2009, background): “Rash after vaccination can be because of the wild-type VZV (median: 8 days; range: 1-20 days) or the VZV vaccine strain (median: 21 days; range: 5-42 days) [284,285].”